• Targos projectmanagement Team and Targos building

  • Targos Lab Team

  • Targos Logistics Team

  • Targos Advance Team

  • Targos Study Office Team

  • Targos employees and Targos building

  • Expert Training by Targos

  • Expert Training - microscope room

Targos - A Leader in Biomarker Services for more than 10 years

Targos GmbH building and staff 2015

Targos core service business is to provide highly standardized development and application of clinical biomarkers for the international pharmaceutical and diagnostic industry.

The company has supported more than 400 international clinical trials since 2005, which have led to the successful approval of several targeted therapies and IVDs for our customers.

The expert team of on-site clinical pathologists operates in a professional environment of project management, logistics, data and quality management. Targos also supports the introduction of new Companion Diagnostic assays into the market.

Targos is a fully GCP-compliant central laboratory that is inspected by the U.S. Food and Drug Administration (FDA). Since 2014 Targos Molecular Pathology GmbH is accredited by the College of American Pathologists and the US-CLIA program.

Targos News

multiplex IHC - click to enlarge
multiplex IHC

June 20, 2019

Definiens & Targos Innovation: AI-powered multiplex IHC biomarker analytic solutions for precision medicine

Collaboration to bolster end-to-end services from assay development to confident informed clinical decision making

Definiens, a leading international Artificial Intelligence (AI)–based biomarker analysis and advanced data mining provider for immuno-oncology research, and Targos, a CAP/CLIA-accredited global leader in clinical trials-led biomarker services, today announced a collaboration for the integration of AI-powered data and multi-omics analytics of the tumor microenvironment with multiplexed immunohistochemistry (IHC) assay development in precision medicine global clinical trial.

"The core of this collaboration unites the power of Definiens' AI-based biomarker analysis and data science expertise with Targos' vast experience in tissue-based biomarker analysis and application in global clinical trials," said Dr. Thomas Henkel, Chief Executive Officer of Targos. "Further joint development of novel multiplexing immunohistological protocols under GCP guidance together with Definiens' unique ability to integrate spatial immune cell distribution and multi-omics analytics will provide new innovative tools spanning from research to the development of new companion diagnostics in immuno-oncology."

»Full press release by Definiens